Novus Therapeutics Reports First Quarter 2019 Financial Results
For the three-months ended March 31, 2019, Novus reported a net loss of $4.9 million, or $0.52 per share, compared to a net loss of $2.8 million, or $0.36 per share, for the same period in 2018.
Read More